Japan · Delayed Price · Currency is JPY Japan Tobacco Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw strong revenue and profit growth, led by robust tobacco business performance and RRP momentum. Management remains confident in full-year guidance, despite geopolitical and cost risks, with increased investment planned for Q2 and beyond.
Fiscal Year 2025
-
Record FY2025 results driven by tobacco and RRP growth, with Ploom Aura expanding to 19 markets and strong pricing power offsetting industry headwinds. FY2026 guidance targets continued profit and cash flow growth, with sustained investment in innovation and shareholder returns.
-
Nine-month results showed strong growth in revenue, profit, and market share, driven by robust tobacco business performance and the Vector Group acquisition. Outlook for FY2025 is revised upward, with record highs expected and a higher dividend. Risks include potential tax hikes in Russia and ongoing inflation in Turkey.
-
Strong first-half results with double-digit AOP and revenue growth, driven by organic momentum and the Vector acquisition. Full-year guidance for revenue and profit was revised upward, while free cash flow was revised down due to litigation and working capital. Dividend guidance was also raised.
-
Q1 2025 saw strong revenue and AOP growth, led by robust tobacco pricing and the Vector acquisition. The pharmaceutical business will be transferred to Shionogi, with a JPY 6 billion profit impact, while the dividend policy remains unchanged. FX volatility and cost increases are key risks.
Fiscal Year 2024
-
Record-high revenue and AOP were achieved in 2024, driven by strong tobacco and RRP growth, with the Vector Group acquisition enhancing U.S. presence and currency resilience. Business Plan 2025 targets high single-digit AOP growth at constant FX, supported by continued investments and robust pricing.
-
Revenue and AOP rose year-on-year, driven by strong tobacco pricing and Ploom growth, while the Vector acquisition boosts US market share and future profit potential. Full-year guidance was revised upward, but profit is tempered by higher costs and Canadian litigation risks.
-
Revenue, profit, and free cash flow all rose year-on-year, driven by strong tobacco pricing and RRP growth. Full-year forecasts for revenue, AOP, and profit were revised upward, while supply chain and FX headwinds remain key risks.